One-Two Punch to Cancer

Thorsten Melcher Ph.D., CBO at RefleXion, and Dr. Giovanni Selvaggi, CEO and CMO at Xcovery, discuss advances in two key areas that could mean a longer life for more Stage 4 patients. The watchwords are customization and personalization. The finding that the customized pairing of two therapies, used in combination, versus in a sequence, creates a synergistic effect, is coupled with the realization every patient's cancer is personalized to their unique system. Developing a plan that includes a patient assessment, multiple treatment options, and how best to combine them, is a promising new direction.

Speakers:
Thorsten Melcher Ph.D. - CBO, RefleXion
Giovanni Selvaggi, M.D. - CEO & CMO, Xcovery

For more information, please visit https://reflexion.com